Table 4. Regression Models for Visual Acuity and Center Point Thickness Outcomes in BRVO Participants†.
| Baseline predictor | Change from Baseline in Visual Acuity Letter Score†† |
Center Point Thickness (um) ††† | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 1 | Year 2 | |||||||||
| Gain of ≥15* |
Loss of ≥15* |
Change from baseline** |
Gain of ≥15* |
Loss of ≥15* |
Change from baseline** |
≤250* | ≥500* | Change from baseline** |
≤250* | ≥500* | Change from baseline** |
|
| 1 mg triamcinolone vs standard care | 0.85 | 0.75 | 1.49 | 0.91 | 3.25 | -5.02 | 0.50 | 1.75 | 82.37 | 0.57 | 3.08 | 103.28-- |
| 4 mg triamcinolone vs standard care | 0.92 | 0.78 | -0.22 | 0.72 | 3.90 | -7.26 | 0.76 | 1.61 | 68.96 | 0.46 | 4.97 | 115.00-- |
| Age (years) | 0.97-- | 1.05-- | -0.42-- | 0.96-- | 1.05 | -0.42-- | 0.98 | 1.01 | 3.46-- | 0.97 | 1.04 | 5.76-- |
| Coronary artery disease (yes: no) | 0.56 | 2.31 | -7.77-- | 0.51 | 3.47-- | -9.39-- | 0.48 | 1.57 | 58.47 | 0.82 | 1.21 | 39.19 |
| Visual acuity letter score | 0.95-- | 1.03 | -0.34-- | 0.94-- | 1.00 | -0.41-- | 1.01 | 0.98 | 3.21-- | 1.00 | 0.96 | 3.30 |
| Duration of macular edema (months) | 0.92 | 1.02 | -0.70-- | 0.90 | 0.99 | -0.66 | 0.96 | 0.99 | 9.72-- | 0.94 | 0.95 | 14.02-- |
| Presence of dense macular hemorrhage (yes: no) | 1.44 | 1.22 | 2.12 | 1.60 | 1.08 | 3.27 | 1.34 | 1.19 | -104.2+ | 1.21 | 1.27 | -103.9+ |
| Prior grid photocoagulation (yes: no) | 0.49 | 1.01 | -4.16 | 1.01 | 1.36 | -1.79 | 0.49 | 1.21 | 144.59-- | 0.65 | 0.90 | 114.09 |
| Center point thickness (per 100 microns) | 0.99 | 1.14 | -0.83 | 1.08 | 1.05 | 0.40 | 0.85 | 1.29-- | -80.11+ | 0.87 | 1.20 | -88.43+ |
| Subretinal fluid (present versus absent) | 0.56 | 1.76 | -4.54 | 0.97 | 1.71 | -2.62 | 0.85 | 1.54 | -76.42+ | 1.21 | 0.55 | -121.7+ |
| Center point thickness after subtracting out subretinal fluid height at center point (per 100 microns) | 1.05 | 1.12 | -0.45 | 1.02 | 1.04 | 0.03 | 0.80-- | 1.24-- | -62.49+ | 0.79 | 1.36 | -62.04+ |
| Area of retinal thickening within the grid (disc areas) | 1.04 | 1.07 | 0.02 | 1.01 | 1.01 | 0.07 | 1.04 | 0.97 | -31.27+ | 0.96 | 1.14 | -21.55+ |
| Area of retinal hemorrhage within the grid (disc areas) | 1.08 | 1.07 | 0.28 | 1.08 | 0.87 | 1.08 | 1.09 | 1.00 | -31.63+ | 1.02 | 1.04 | -31.09+ |
| Area of fluorescein leakage within the grid (disc areas) | 0.98 | 1.06 | -0.28 | 0.96 | 1.06 | -0.31 | 1.10 | 0.92 | -31.95+ | 0.96 | 1.07 | -22.71+ |
BRVO = branch retinal vein occlusion; FDR = False Discovery Rate
Effects with FDR < 0.05 are noted in bold. Variables for which FDR ≥ 0.05 in all 12 outcomes have been deleted from this table. Plus (+) superscript on estimates indicates beneficial effect on vision. Minus (--) indicates detrimental effect on vision.
For change from baseline in visual acuity letter score, an effect on vision is considered beneficial if it increases the odds of gain, decreases the odds of loss or increases the positive change from baseline.
For macular thickness, an effect on vision is considered beneficial if it increases odds of a thin macula, decreases odds of a thick macula, or decreases the positive change from baseline.
estimates are odds ratios
estimates are beta coefficients